
Opinion|Videos|April 22, 2024
Future Landscape of cGvHD Management
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Discussing perspectives on the future landscape of chronic GvHD management, including limitations of current targeted treatment options and emerging research of interest.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5

























